🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

View Full Press Release: accessiblemeds.org/resources/pres…

Advocacy groups, health networks and others back bill seeking to nix 'interchangeable' biosim tag fiercepharma.com/pharma/advocac…

The negative effect of #tariffs include: - Triggering unprecedented drug shortages for the American people - Raising prices on the most affordable prescription drugs in the U.S. market today Get the Facts: accessiblemeds.org/wp-content/upl…

‘Patent thickets and litigation abuses hinder all biosimilars’ READ in Chain Drug Review: chaindrugreview.com/patent-thicket… Chaindrugreview AAM

⚖️ The Legal & Policy Track digs into patent law, market delays and onshoring at #GRxBiosims 2025. ⏰ Early bird savings end July 11. Save your seat now! grxbiosims.org

'Hikma's planned $1B US investment comes at critical time for generic medicines supply' READ in Pharma Manufacturing: pharmamanufacturing.com/all-articles/a…

Have you been to The Atlantic website recently? Navigate there through early September to check out video footage from our 2024 discussion on "The Next Frontier of Affordable Medicines" featuring #generic and #biosimilar medicines industry leaders, members of #Congress, top

NEW TODAY: Matrix Global Advisors analysis shows Medicare Drug Price Negotiation has chilling effect on development and availability of #generic and #biosimilar medicines READ: accessiblemeds.org/wp-content/upl… Biosimilars Council

“Almost all the Medicare negotiated drugs have a generic or biosimilar equivalent in the pipeline, which in turn have a significantly lower cost,” said John Murphy, President and CEO of AAM. “The Medicare drug price negotiation program artificially extends the lifecycle of the

#AAM's General Counsel, Karin Hessler, joined forces with US-MADE and United4PatentReform yesterday on Capitol Hill - providing insights on protecting America's economic and national security interests from the threat of bad patents.

.Matrix Global Advisors (MGA) Releases New White Paper on Medicare Price Negotiations and Drug Competition: “If a brand drug’s price could be set by the government prior to generic entry, generic drugmakers’ incentives to undertake the risk and expense associated with bringing a generic to

Conservatives Must Rally Behind Generic Drugs dlvr.it/TLwsNd

Welch, Hawley, Klobuchar Introduce Bipartisan Legislation to Streamline Drug Patent Litigation, Lower Cost of Prescription Drugs “Patent thickets increasingly serve as a barrier to patient access to lower-cost generic and biosimilar medicines. This bill proactively addresses

Upcoming biologic patent expiries are spread across 13 broad therapeutic areas. However, the #biosimilar pipeline does not reflect this diversity. Addressing the #biosimilarvoid means driving massive savings for patients undergoing treatment for serious medical conditions –